key: cord-0905665-r4o240qq authors: Yue, Lei; Cao, Han; Xie, Tianhong; Long, Runxiang; Li, Hua; Yang, Ting; Yan, Min; Xie, Zhongping title: N‐terminally truncated nucleocapsid protein of SARS‐CoV‐2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactive SARS‐CoV‐2 date: 2020-09-23 journal: J Med Virol DOI: 10.1002/jmv.26541 sha: db1d4d50aeb8127085770db919bf8dfe7fcd9810 doc_id: 905665 cord_uid: r4o240qq The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) had led to a serious public health crisis, and no specific treatments or vaccines are available yet. A nucleocapsid protein (NP)‐based enzyme‐linked immunosorbent assay (ELISA) detection method is not only important in disease diagnosis, but is required for the evaluation of vaccine efficacy during the development of an inactivated SARS‐CoV‐2 vaccine. In this study, we expressed both the NP and N‐terminally truncated NP (ΔN‐NP) of SARS‐CoV‐2 in an Escherichia coli expression system, and described the purification of the soluble recombinant NP and ΔN‐NP in details. The identities of the NP and ΔN‐NP were confirmed with mass spectrometry. We then used IgG detection ELISAs to compare the sensitivity of NP and ΔN‐NP in detecting anti‐SARS‐CoV‐2 antibodies. ΔN‐NP showed greater sensitivity than NP in the analysis of serially diluted sera from mice and rabbits vaccinated with inactive SARS‐CoV‐2 and in human sera diluted 1:400. ΔN‐NP showed a positive detection rate similar to that of the SARS‐CoV‐2 S protein in human sera. We conclude that ΔN‐NP is a better serological marker than NP for evaluating the immunogenicity of inactivated SARS‐CoV‐2. This article is protected by copyright. All rights reserved. The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to threaten global public health. Several vaccines have already completed phase II clinical trials [1] [2] [3] [4] , although there are not appropriate therapies for COVID-19 5 . Accurate serological diagnostic strategies are the first step in inhibiting the spread of SARS-CoV-2 and allow the qualitative and quantitative study of the immune responses to SARS-CoV-2 6, 7 . The vaccine development process also requires that antibody responses and serological conversion can be determined accurately. During the SARS-CoV outbreak in 2003, researchers considered the truncated nucleocapsid protein (NP) a good marker for diagnostic purposes 8 . An enzyme-linked immunosorbent assay (ELISA) based on the NP of SARS-CoV-2 has also been used in the serodiagnosis of this novel coronavirus disease This article is protected by copyright. All rights reserved. 9 . An antibody directed against NP is more sensitive than one directed against the spike protein in detecting early infections 10 . However, there are some controversial findings about the non-specific of NP. Guo and colleagues showed that recombinant whole NP did not cross react with antibodies directed against other common coronaviruses 9 . However, Yutaro et al. reported that full-length NP (FL-NP) had a higher false positive rate than N-terminally truncated NP (ΔN-NP) in sera diluted1:100. They concluded that ΔN-NP is better suited than FL-NP to the development of highly sensitive diagnostic assays for COVID-19 11 . This suggests that an ΔN-NP-based ELISA has potential utility in evaluating the efficacy of inactivated SARS-CoV-2 vaccines. Because the antibody response to NP and its serological conversion in rodents and humans must be detectable during the development of inactivated SARS-CoV-2 vaccines, it is essential to enhance the sensitivity of such an assay to detect low levels of immunoglobulin G (IgG) in mice or humans, especially during the earlier period soon after vaccination. To address this issue, we used ΔN-NP to develop ELISAs with which to detect anti-SARS-CoV-2 NP antibodies in mouse, rabbit, and human serum. Our results indicated that SARS-CoV-2 ΔN-NP is more sensitive than NP for evaluating the immune effects of an inactivated SARS-CoV-2 vaccine. This article is protected by copyright. All rights reserved. Balb/c mice and Japanese white rabbits were purchased from ChuShangKeJi Co. College. For healthy volunteers vaccinated with a candidate inactivated SARS-CoV-2 vaccine or placebo, written informed consent was obtained from each person before enrollment. The candidate inactivated SARS-CoV-2 vaccine was provided by Dr. Qihan Li The plasmid expressing NP of SARS-CoV-2 was constructed and kindly provided This article is protected by copyright. All rights reserved. The plasmid extracted from the clones was doubly digested with EcoRI and XhoI to confirm the presence of the insert. DNA sequencing confirmed that the insert was in-frame and contained no extraneous changes. Escherichia coli BL21(DE3) cells (TsingKe) were transformed with the NP or ΔN-NP construct. The cells were plated on LB agar containing kanamycin (50 μg/ml) and grown overnight at 37 °C. A single colony was used to inoculate 10 ml of LB starter culture supplemented with kanamycin (50 μg/ml), which was incubated at 37 °C overnight. An aliquot (5 ml) of the starter culture was added to 500 ml of LB medium and grown at 37 °C with shaking (225 rpm) until the optical density at a wavelength of 600 nm (OD 600 ) reached ~0.6 (about 3 h). Protein expression was induced with isopropyl β-D-thiogalactoside (IPTG) at 37 °C or 24 °C. The bacterial pellets were harvested by centrifugation (6500 × g for 15 min at 4 °C) for 4 or 20 h. The harvested cells were resuspended in phosphate-buffered saline (PBS; 10 mL/g wet bacteria), incubated on ice for 10 min, and disrupted by sonication (Ningbo Scientz Biotechnology Co., Ltd). The lysates were centrifuged at 12,000 × g for Protein concentrations were quantified with the Pierce™ BCA Protein Assay Kit (Thermo Scientific). The protein sample (20 μg) was loaded onto 10% gel for SDS-PAGE. After concentration at 80 V for 20 min, the sample was separated at 120 V for 90 min. The gel was stained with CBB and decolored until the bands were clearly visible. This article is protected by copyright. All rights reserved. The identities of SARS-CoV-2 NP and ΔN-NP were confirmed with trypsin digestion followed by LC-MS/MS analysis (Novogene). Briefly, a CBB-stained protein band from the IMAC purification was excised from the acrylamide gel in a cube of approximately 1 mm 3 , and digested with trypsin at 37 °C overnight. The To detect IgG, 96-well plates (Corning) were coated with 100 μl per well of spike (S1) protein, NP, or ΔN-NP and incubated at 4 °C overnight. The coating solution was removed and 100 μl per well of 2% bovine serum albumin (BSA) prepared in PBS with 0.1% Tween 20 (PBST) was added to the plates at room temperature for This article is protected by copyright. All rights reserved. 1 h as a blocking solution. Serial dilutions of rabbit serum were prepared in 1% BSA in PBST. The blocking solution was removed and 100 μl of each serial dilution was added to the plates for 2 h at room temperature followed by washing. The data are presented as the means ± SEM of the indicated number of experiments. The statistical significance of differences between multiple treatments was determined with one-way analysis of variance and Tukey's post hoc honest significance test. All statistical analyses were performed with the GraphPad Prism software version 7 (GraphPad Software Inc., La Jolla, CA). To produce soluble NP and ΔN-NP, E. coli BL21(DE3) cells were transformed with the pET28a-N and pET28a-ΔN vectors, respectively, and expression was protein when we reduced the expression temperature to 24 °C (Fig. 1 ). Soluble NP and ΔN-NP were purified by immobilized metal affinity chromatography (IMAC) on a 5 ml HisTrap™ HP column. The NP and ΔN-NP proteins were eluted with a 25-250 mM imidazole gradient ( Fig. 2A, 2C ). After purification, NP and ΔN-NP appeared as single bands (Fig. 2B, 2D) . The identities of NP and ΔN-NP were confirmed with LC-MS/MS (97.73% and 96.52% Abundance, respectively). Together, these data demonstrate that our recombinant NP and ΔN-NP proteins were of high quality and homogeneous, and This article is protected by copyright. All rights reserved. that the estimated masses matched those of the mature native N protein of SARS-CoV-2. To assess the sensitivity of NP and ΔN-NP based ELISA, we performed an IgG detection ELISA to analyze inactive SARS-CoV-2 vaccinated sera. The ΔN-NP ELISA showed higher IgG titers than NP in serial diluted mouse and rabbit sera ( Fig. 3) . We then tested IgG in 30 volunteer sera collected on day 28 after vaccination with a candidate inactive vaccine or placebo. ΔN-NP showed similar positive rate similar to that achieved with the SARS-CoV-2 S protein in human sera diluted 1:400 (Fig. 4) . In contrast, the NP-based ELISA exhibited lower IgG titers and had a lower positive rate than both the ΔN-NP-and S-protein-based ELISAs. In the development of an inactivated SARS-CoV-2 vaccine, the antibody response to the candidate vaccine and its serological conversion must be determined. However, some findings about the sensitivity of NP-based ELISAs have been controversial. In this study, we confirmed that ΔN-NP is better than NP as a serological marker for evaluating the immunogenicity of inactivated SARS-CoV-2. SARS-CoV-2 detection with an NP-based ELISA is widely used to screen individuals for COVID-19. It has been reported that the specificity of NP detection is good in clinical samples 9 . However, several studies have also shown that the specificity and sensitivity of full-length-NP-based ELISAs in the diagnosis of COVID-19 are lower than those of the ΔN-NP-based ELISAs 11 . ΔN-NP has also been used by Yu et al. to reduce the high rates of false positive results when testing healthy donor sera for SARS-CoV 12 . These findings suggest that ΔN-NP could be used for ELISA-based immunogenicity assay. Consistent with patient serum, our results demonstrate that ΔN-NP is more sensitive in evaluating the immunogenicity of inactivated SARS-CoV-2 than is NP. As Yamaoka Y et al. pointed out 11 , although the amino acid sequences of the entire NP of other Coronaviruses are dissimilar to that of SARS-CoV-2, the conserved residues at the N-terminal domain of NP show a high degree of similarity. This may lead to high cross reactivity of NP with antibodies to other human coronaviruses. ΔN-NP, which was devoid of the homogenous conserved residues at the N-terminal region, is confirmed better suited than NP to develop high sensitivity diagnostic assays for both SARS-CoV 8 and SARC CoV-2 11 . According to these studies, truncated NP is very likely to be a good marker in Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 A serological assay to detect SARS-CoV-2 seroconversion in humans Evaluation of inapparent nosocomial severe acute respiratory syndrome coronavirus infection in Vietnam by use of highly specific recombinant truncated nucleocapsid protein-based enzyme-linked immunosorbent assay Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease Whole nucleocapsid protein of SARS-CoV-2 may cause false positive results in serological assays Recombinant truncated nucleocapsid protein as antigen in a novel immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of severe acute respiratory syndrome coronavirus infection We thank Dr. Feng Cong (Guangdong Laboratory Animals Monitoring Institute, Guangdong, China) for providing the SARS-CoV-2-N expression plasmid. The authors have declared that no competing interests exist. This article is protected by copyright. All rights reserved. The data that support the findings of this study are available from the corresponding author upon reasonable request.